Bayer considers expanding use of Nubeqa on new data from prostate cancer trial
Bayer said its drug Nubeqa was shown to slow the progression of a certain type of prostate cancer in a late-stage trial, bolstering growth prospects for one of the German drugmaker’s key pharmaceuticals. The drug is already approved in other prostate cancer treatments.
ENTRADAS POPULARES
Putin may discuss Ukraine peace deal with Trump
noviembre 22, 2024
Spain’s vice-president Ribera blames floods on climate change
noviembre 22, 2024
Storm lashes northwestern US, killing two people
noviembre 22, 2024
Iceland volcano erupts for tenth time in three years
noviembre 22, 2024
TRANSMISIÓN EN VIVO